Renfu Pharmaceutical (600079.SH): Oxicam sustained-release tablets are granted provisional approval number by the US FDA.

Zhitong Finance APP News, Renfu Medicine (600079.SH) announced that the company's controlling subsidiary, Wuhan Renfulikang Pharmaceutical Co., Ltd. (referred to as "Renfulikang"), has received a provisional approval number from the Food and Drug Administration (FDA) of the United States for its Oxcyphen XR extended-release tablets. Oxcyphen XR extended-release tablets are used to treat partial seizures in patients aged 6 and above with epilepsy.